Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01809717 · ClinicalTrials.gov registry record · NA
Multiple Myeloma and Exercise
A NA study of Newly Diagnosed Multiple Myeloma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01809717 is a NA study of Newly Diagnosed Multiple Myeloma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01809717, a NA study of Newly Diagnosed Multiple Myeloma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.
Conditions Studied
Interventions
- OTHER Weight Lifting Exercises
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the Unviersity of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01809717
The ClinicalTrials.gov registry entry for NCT01809717 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Newly Diagnosed Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Weight Lifting Exercises is the first listed.
NCT01809717 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01809717 about?
NCT01809717 is a clinical study titled "Multiple Myeloma and Exercise". This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.
What is the current status of trial NCT01809717?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2013-03. Estimated completion is 2013-08.
What conditions does trial NCT01809717 study?
This clinical trial studies the following conditions: Newly Diagnosed Multiple Myeloma.
What interventions are being tested in trial NCT01809717?
The interventions under investigation include: Weight Lifting Exercises (OTHER).
Who is sponsoring clinical trial NCT01809717?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01809717 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Newly Diagnosed Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RECRUITING · Phase 3
-
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.